Skip to main content
Clinical Trials/DRKS00033099
DRKS00033099CompletedUnknown

Absorption of X-Pro-Dipeptides following Oral Ingestion - X-PRO

Institut für Pharmakologie, Universitätsmedizin Greifswald0 sites9 target enrollmentStarted: November 24, 2023Last updated:
Conditions

Trial Snapshot

Phase
Unknown
Status
Completed
Sponsor
Enrollment
9

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
N/a: Single Arm Study
Masking
Open (masking not used)

Eligibility Criteria

Ages
18 Years to 40 Years (—)
Sex
All

Inclusion Criteria

  • understands the study purpose and design
  • - contractually capable and provides signed informed consent form
  • - healthy condition or mild and/or well treated forms of allergies, asthma,
  • hypertension, and orthopedic diseases
  • - a maximum of 2 chronically taken drugs

Exclusion Criteria

  • a.BMI > 35 kg/m2 and <18 kg/m2
  • b.known pregnancy or lactation period
  • c.women: positive urine pregnancy test at screening or pharmacokinetic
  • d.anemia (hemoglobin < 13 g/dl (8,07 mmol/l) in men or < 12 g/dl (7,45
  • mmol/l) in women
  • e.blood donation within the last 4 weeks
  • f.elevated liver function tests (ALAT, ASAT, yGT, Bilirubin > 2x ULN)
  • g.reduced renal function (eGFRMDRD < 60 ml/min/1,7m2)
  • h.known history of coeliac disease or gluten intolerance
  • i.psychiatric disease or drug dependency
  • j.use of recreational drugs more than twice a week
  • k.poor venous conditions that make it impossible to place a peripheral
  • venous catheter and regularly draw blood through it

Investigators

Sponsor
Institut für Pharmakologie, Universitätsmedizin Greifswald

Similar Trials